Abstract PS05-04: [89Zr]Trastuzumab-PET/MRI to Characterize HER2+ Breast Cancer: A Quantitative Approach on Tumor Heterogeneity
Authors: Ameer Mansur, Moozhan Nikpanah, Johnathan McConathy, Erica Stringer-Reasor, Gabrielle Rocque, Ahmed Elkhanany, Katia Khoury, Nusrat Jahan, Suzanne Lapi, Anna Sorace
Journal: Cancer Research (2024)

Abstract Introduction: Molecular imaging of human epidermal receptor 2 (HER2) aims to overcome limitations of traditional HER2 assessment through biopsy, including invasiveness and inability to detect intra and inter-tumoral spatial heterogeneity. Prior human studies suggest that [89Zr]Trastuzumab-positron emission tomography (PET) imaging can effectively differentiate HER2 lesions (Dehdashti et al, Breast Cancer Res. Treat. 2018). Commonly, CT complements PET for anatomical reference, however, integrating MRI enables the sensitivity of soft-tissue contrast required for anatomic and morphological breast imaging and can provide for quantitative multiparametric characterization. Diffusion weighted-MRI (DW-MRI) contributes to tumor characterization by assessing intratumoral cellularity via the apparent diffusion coefficient (ADC), and can be combined with molecular expression from HER2-PET. We present preliminary results in 13 patients with HER2 PET/MRI to define tumor and normal tissue imaging metrics. Methods: A phase II clinical trial assessing the feasibility of [89Zr]trastuzumab-PET with simultaneous quantitative DW-MRI to enhance understanding of tumor heterogeneity in patients with HER2-positive metastatic breast cancer. 13 patients (ages 40-70; mean 60) with HER2-positive breast cancer based on prior biopsy underwent whole-body [89Zr]trastuzumab-PET/MR imaging (5 ± 1 days post-injection of radiopharmaceutical) during the course of HER2-directed therapy. Normal organ and tumor regions of interest (ROI) were identified on concurrently acquired whole-body T1-weighted MRI for ADC (cellularity) and standardized uptake value (SUV, PET uptake) mean quantification. Tumor presence was confirmed via bone scintigraphy, FDG-PET/CT, or contrast-enhanced MRI. Non-parametric T-tests compared lesions to normal organs. Lesions greater than 30 mm in diameter underwent multiparametric intratumoral habitat analysis. Using the median HER2 values, tumors were evaluated for heterogeneity of high and low HER2 expression in conjunction with ADC. Long-term treatment response evaluation is ongoing. Results: Mean [89Zr]trastuzumab uptake, SUV, and ADC values for normal tissue were summarized in Table 1. All tumors demonstrated higher overall uptake of [89Zr]trastuzumab (bone: p=0.019, brain: p=0.014, breast: p=0.069, juxtapulmonary: p=0.026) and increased ADCmean values (bone: p=0.002, brain: p=0.5, breast: p=0.03, juxtapulmonary: p=0.037), in comparison to matched normal organs. Notably, one of five patients with a breast lesion, who completely responded to HER2 targeted therapy, exhibited the highest breast lesion SUVmean. Brain and lymph node lesions demonstrated intratumoral heterogeneity of HER2 expression. Conclusion: Our study demonstrates the potential value of quantitative MRI along with molecular imaging to characterize metastatic HER2+ breast cancer and evaluate intratumoral heterogeneity. We underscore the importance of standardizing processing techniques and contribute to this effort by summarizing [89Zr]trastuzumab uptake and cellularity values of normal physiological uptake. Higher SUVmean and ADC mean values observed in lesions, compared to normal tissue, highlight their potential roles in intratumoral classification. While studies have shown the utility of [89 Zr]trastuzumab-PET/CT, our findings demonstrate that integrated DW-MRI can aid in tumor classification. Table 1: Physiological 89Zr-Trastuzumab Uptake (SUVmean) and Apparent Diffusion Coefficient (ADCmean) in Healthy Tissues Citation Format: Ameer Mansur, Moozhan Nikpanah, Johnathan McConathy, Erica Stringer-Reasor, Gabrielle Rocque, Ahmed Elkhanany, Katia Khoury, Nusrat Jahan, Suzanne Lapi, Anna Sorace. [89Zr]Trastuzumab-PET/MRI to Characterize HER2+ Breast Cancer: A Quantitative Approach on Tumor Heterogeneity [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PS05-04.